Synlogic

Synlogic

Powering the microbiome with synthetic biotics

Human health & social work | United States of America | Disease Specific Prevention and Mitigation |

 Profile Provided By: Company Website

Overview

At Synlogic we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields synthetic biology and the microbiome.Using our synthetic biotics platform we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these synthetic biotics orally where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical as in stimulation of immune effectors to combat certain tumors.We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also hard at work on synthetic biotics to address more prevalent conditions including inflammatory bowel disease (IBD) cancer and metabolic conditions such as diabetes and obesity.

Industry

Legal Structure

Operating Status

Employees

Human health & social work C Corporation Operating 11 - 50 employees

Funding and Financing Rounds


Team


Impact

Social Objectives:

Environmental Objectives:

Operational Impact:


Impact Reports & Metrics


Offices

Headquarters

200 Sidney St.
Suite 320
Cambridge, Massachusetts 02139
United States of America



Explore

Revision History


Quick Search



  • Global  
  • Africa  
  • Americas  
  • Asia  
  • Europe  
  • Oceania  


News & Links

Incoming

Tags

COPYRIGHT 2017 IMPACTSPACE. ALL RIGHTS RESERVED.